Citius Pharmaceuticals is trading 5.04% higher at $0.50 in pre-market, with no clear company-specific catalyst identified for the move. - The latest company announcement found was its October 12 investor-conference participation notice. - October 13 coverage reported an FDA decision requiring enhanced product testing for LYMPHIR; neither this coverage nor modestly higher major indices establishes a reason for the gain.